Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (NASDAQ: APYX) is a surgical aesthetics and advanced energy technology company whose news flow centers on its Helium Plasma Platform Technology products, including Renuvion, the AYON Body Contouring System, and J-Plasma. Company press releases focus on developments in the cosmetic surgery market, the hospital surgical market, and OEM relationships with other medical device manufacturers.
Investors and observers following APYX news will see regular updates on financial performance, such as quarterly and annual revenue results, preliminary unaudited revenue ranges, and segment-level trends in Surgical Aesthetics and OEM revenue. The company also issues guidance updates and discusses factors influencing its revenue mix, including the commercial rollout of AYON and demand for single-use handpieces and generators.
Another key category of Apyx Medical news involves product and regulatory milestones. Recent announcements describe FDA 510(k) clearances and submissions related to the AYON Body Contouring System, as well as international regulatory approvals like the Ministry of Food and Drug Safety clearance in South Korea for the Apyx One console and single-use handpieces. These items highlight how the company is expanding the indications and geographic reach of its platforms.
APYX news also covers capital markets and corporate actions, including proposed and completed public offerings of common stock under an effective Form S-3 shelf registration statement, as reported in 8-K filings and related press releases. Additional items include notices of investor conference participation, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and information about annual stockholder meetings and governance matters.
This news page aggregates these disclosures so readers can review Apyx Medical’s earnings releases, product launch updates, regulatory submissions, financing transactions, and investor events in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Apyx Medical Corporation (NASDAQ:APYX) announced that it will release its financial results for Q1 of fiscal year 2023 before the market opens on May 11th. A conference call will follow at 8:00 a.m. Eastern Time on the same day, allowing for a discussion of the results and a Q&A session. Interested callers can join by dialing 877-407-8289 (or 201-689-8341 internationally) with access code 13737575. A live webcast will also be available through the Company’s Investor Relations section. This financial update is anticipated to provide insights into Apyx Medical's performance in the advanced energy technology market, including its innovative products Renuvion and J-Plasma, which are designed for cosmetic and hospital surgical applications.
Summary not available.
Apyx Medical Corporation (NASDAQ:APYX) reported its Q4 and full year 2022 results, revealing a 25% decline in total revenue to $12.6 million for Q4, and a 8% decrease for the year to $44.5 million. Advanced Energy revenue dropped 30% year-over-year to $10.5 million in Q4, while OEM revenue increased 15%. The company experienced a net loss of $6.0 million for Q4, worsening from $2.0 million a year earlier, and a loss of $23.2 million for 2022. Looking ahead, Apyx anticipates 2023 revenue between $58.0 million and $61.0 million, indicating a potential growth of 30% to 37% year-over-year. Key developments included the launch of a new marketing campaign and a secured $35 million credit facility.
Apyx Medical Corporation (NASDAQ:APYX) has received 510(k) clearance from the U.S. FDA for its Renuvion APR Handpiece. This device is approved for delivering radiofrequency energy and/or helium plasma for soft tissue coagulation and contraction, specifically subcutaneous tissue. CEO Charlie Goodwin emphasized this clearance underscores Renuvion's safety and effectiveness. Apyx is currently seeking an additional indication for use following liposuction, which remains under FDA review. The company specializes in advanced energy technology, aiming to elevate patient outcomes in cosmetic and surgical markets.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
